The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy

摘要

Hydroxyurea (HU) is largely used for the treatment of chronic myeloproliferative disorders (CMPD). It is the first-choice therapy in patients with essential thrombocythemia aged > 60, where it can effectively reduce the incidence of vascular events , Data on the frequency of intolerance/resistance to chronic HU therapy are scarce. Hematologic resistance has been reported in 3.7-7.0% of cases and side effects causing HU discontinuation in 7.7-13% of cases after a median of 3 years . Recently, an objective definition of clinical resistance or intolerance to HU in ET has been published , providing the basis for future studies.